Lyndsay N. Harris

Papers

1

Total Citations

42

H-Index

1

About

Lyndsay N. Harris is a leading oncologist and translational researcher whose work has fundamentally shaped the understanding and treatment of breast cancer, particularly HER2-positive disease. Her research bridges the critical gap between laboratory discovery and clinical application, with a focus on identifying blood-based biomarkers for early detection and monitoring therapeutic response. In her seminal 2006 study, Harris demonstrated that declining plasma fibrinogen alpha fragments could identify HER2-positive breast cancer patients and, notably, revert to normal levels after surgical resection—a finding that has garnered 42 citations and opened new avenues for non-invasive diagnostics. This work underscores her commitment to developing simple, blood-based tests that could complement radiological screening and improve sensitivity of detection for the most common nonskin malignancy affecting women. Beyond this landmark paper, Harris has made enduring contributions to precision oncology, advancing our understanding of how molecular subtypes of breast cancer respond to targeted therapies. Her research continues to influence clinical practice, offering hope for earlier detection and more personalized treatment strategies that ultimately improve patient outcomes.

Research Focus

Key Achievements

1
H-Index
1
Papers
42
Total Citations
42
Avg Citations/Paper
🏆 Most Cited Paper
Declining Plasma Fibrinogen Alpha Fragment Identifies HER2-Positive Breast Cancer Patients and Reverts to Normal Levels after Surgery
42 citations · 2006
📈 Most Prolific Year: 2006 (1 Papers)
🤝 Key Collaborators: 7

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago